Effects of valganciclovir on spermatogenesis in renal transplant patients - results of a multicenter prospective nonrandomized study.

ABSTRACT: Ganciclovir (GCV) inhibits spermatogenesis in preclinical studies but long-term effects on fertility in renal transplant patients are unknown. In a prospective, multicenter, open-label, nonrandomized study, male patients were assigned to Cohort A [valganciclovir (VGCV), a prodrug of GCV] (n = 38) or B (no VGCV) (n = 21) by cytomegalovirus prophylaxis requirement. Changes in semen parameters and DNA fragmentation were assessed via a mixed-effects linear regression model accounting for baseline differences. Sperm concentration increased post-transplant, but between baseline and treatment end (mean 164 days Cohort A, 211 days Cohort B), the model-based change was lower in Cohort A (difference: 43.82 × 10⁶ /ml; P = 0.0038). Post-treatment, sperm concentration increased in Cohort A s

SUBMITTER: McLeroth P 

PROVIDER: S-EPMC7065128 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature